Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Orchestra BioMed Holdings, Inc.

Get SEC filing alerts via email and in your feed for Orchestra BioMed Holdings, Inc.

OBIO

Orchestra BioMed Holdings, Inc.

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. develops innovative medical devices and bioelectronic therapies targeting large markets such as hypertension and artery disease. Its core products include AVIM therapy, a device-based hypertension treatment integrated into pacemakers, and Virtue SAB, a drug/device combo for artery disease. The company partners with industry leaders like Medtronic and Terumo to accelerate product development, commercialization, and global market access.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Orchestra BioMed Holdings, Inc.

1
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports $110.9 Million Revenue in Q1 2026, Net Loss Increases to $20.7 Million

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports $32.9M Partnership Revenue Surge and $52.7M Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports $2.57 Million Revenue and $58.95 Million Net Loss for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports 7% Revenue Growth in Q2 2025 Amid Increased Losses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports 40% Revenue Growth to $868,620 in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports $61M Net Loss and 4% Revenue Decline for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Orchestra BioMed Holdings, Inc. Orchestra BioMed Reports 136% Revenue Growth in Q3, Net Loss Increases Amid Increased Expenses and Investments

Via official filing (AI summary) | over 1 year ago | 0 comments